The best time and recommendations for taking baricitinib/alemin

Baricitinib (Baricitinib) is a highly selectiveJAK1/2 inhibitor, used to treat immune-related diseases such as rheumatoid arthritis and alopecia areata. Although the absorption rate of this drug is affected by food, the overall clinical significance is not significant. It is still necessary to pay attention to the scientific way of taking the drug to ensure the stability and safety of the drug. According to FDA and EMA information, the recommended dose of baricitinib is usually taken orally once a day, with food or on an empty stomach. However, in order to reduce drug-drug interactions and improve compliance, it is recommended to take it at a fixed time every day.

Research shows that high-fat meals can slightly reduce the plasma concentration of baricitinib (AUC and Cmax decrease by about 11%-14% on average) and delay Tmax by about 0.5 hours. However, this effect does not reach clinically significant levels, so patients can choose to take it before or after meals according to their own habits. For those with sensitive stomachs or those taking other medications at the same time, it is recommended to take it after meals to reduce stomach discomfort. For patients with chronic diseases who need to control the consistency of drug absorption, they can choose to take the drug on an empty stomach in the morning to make the blood drug concentration more stable.

When taking the medicine, the tablet should be swallowed whole and should not be broken or crushed to avoid affecting the drug release rate. If you miss a dose, you should take it as soon as possible, but if it is close to the next dose, it is not recommended to double the dose. Patients who take baricitinib for a long time should maintain regularity and should not stop taking baricitinib without authorization due to symptom relief, otherwise it may lead to disease rebound or immune response relapse.

At the same time, patients should avoid concurrent use with potentCYP3A4 inhibitors or inducers to prevent drug metabolism from being affected. For people with impaired kidney function, doctors will adjust the dose based on glomerular filtration rate (eGFR), because baricitinib is primarily excreted through the kidneys. Patients with abnormal liver function should also use it with caution.

Reference materials:https://go.drugbank.com/drugs/DB11817